Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 946-949

  Fujita, K ^a,b   Ichikawa, W ^a   Yamamoto, W ^a   Endo, H ^a   Nagashima, F ^a,b   Tanaka, R ^a   Miya, T ^a   Araki, K ^a   Kodama, K ^a   Sunakawa, Y ^a   Narabayashi, M ^a   Miwa, K ^a   Ando, Y ^a   Akiyama, Y ^a,b   Kawara, K ^a   Sasaki, Y ^a,b  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

5 FU; Japanese; Large body surface area; Pharmacokinetics; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG EXPOSURE; FEMALE; HUMAN; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STOMACH CANCER;

EID: 65549088595     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn718     Document Type: Article

References (15)

1. Kubota T. The role of S-1 in the treatment of gastric cancer. Br J Cancer 2008; 98: 1301-1304.
2. Ikeda K, Yoshisue K, Matsushima E et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000; 6: 4409-4415.
3. Nakajima M, Fukami T, Yamanaka H et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006; 80: 282-297.
4. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78: 748-755.
5. Shiotani T, Weber G. Purification and properties of dihydrothymine dehydrogenase from rat liver. J Biol Chem 1981; 256: 219-224.
6. Baker SD, Verweij J, Rowinsky EK et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002; 94: 1883-1888.
7. Gurney H. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-2611.
8. Traina TA, Theodoulou M, Feigin K et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 2008; 26: 1797-1802.
9. Shirao K, Hoff PM, Ohtsu A et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: Joint United States and Japan study of UFT/LV. J Clin Oncol 2004; 22: 3466-3474.
10. Fujita K, Yamamoto W, Endo S et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci 2008; 99: 1049-1054.
11. Ichikawa W, Fujita K, Sasaki Y. The unanswered question: What is the determinant of S-1 pharmacokinetics? Clin Pharmacol Ther 2008; 84: 203.
12. Hirata K, Horikoshi N, Aiba K et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 2000-2005.
13. Mcintosh JF, Möller E, van Slyke DD. Studies of urea excretion. III. The influence of body size on urea output. J Clin Invest 1928; 6: 467-483.
14. Ajani JA, Lee FC, Singh DA et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 663-667.
15. Jeung HC, Rha SY, Kim HK et al. Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist 2007; 12: 543-554.